Immobilisation of plasminogen activator within porous alumina matrix for creation of new thrombolytic materials

A major obstacle in the development of new enzyme-based thrombolytic systems is their low stability and extremely short period of half-life (usually, less than 2-6 min of the circulation half-life), which requires their administration in large doses to obtain therapeutic effects, and, therefore, inevitably leads to a significant incidence of hemorrhagic complications. Here, we point out to a potential solution of this problem by developing a new family of injectable composites for thrombolysis: plasminogen activator entrapped within alumina. In that case alumina is a pertinent drug carrier developed to prolong activity in vivo, to reduce the total administered dose of the drug necessary for the treatment, and to decrease its side effects.